BRAF and melanoma: Although the exact role of AEBP1 in CAFs in melanoma patients requires further analysis, Hu and colleagues [52] conducted a detailed experiment to examine the potential role of AEBP1 in acquired drug resistance to BRAF inhibition of melanoma via NF-κB pathway.